KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest Expenses (2023 - 2025)

Historic Interest Expenses for Travere Therapeutics (TVTX) over the last 9 years, with Q3 2025 value amounting to $2.8 million.

  • Travere Therapeutics' Interest Expenses changed 0.0% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 111.4%. This contributed to the annual value of $11.2 million for FY2024, which is 118.23% down from last year.
  • Travere Therapeutics' Interest Expenses amounted to $2.8 million in Q3 2025, which was down 0.0% from $2.8 million recorded in Q2 2025.
  • Travere Therapeutics' Interest Expenses' 5-year high stood at $2.9 million during Q1 2025, with a 5-year trough of $2.8 million in Q1 2024.
  • Its 3-year average for Interest Expenses is $2.8 million, with a median of $2.8 million in 2023.
  • Per our database at Business Quant, Travere Therapeutics' Interest Expenses crashed by 151.25% in 2024 and then skyrocketed by 357.14% in 2025.
  • Quarter analysis of 3 years shows Travere Therapeutics' Interest Expenses stood at $2.8 million in 2023, then dropped by 0.74% to $2.8 million in 2024, then changed by 0.0% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $2.9 million during Q1 2025.